Thyroid cancer detection kit PC219010101

oncologyRET geneRET fusion

The RET proto-oncogene is located at 10q11.2, is 60 kb in length, and contains 21 exons. After the RET gene is fused, the dimerization can be completed without ligands, resulting in the RET tyrosine kinase region, downstream MAPK、 PI3K/AKT and other signal pathways are continuously activated. It continues to drive cell proliferation, migration and differentiation etc., which will cause the occurrence of tumors. RET is one of the most common driver genes for papillary thyroid carcinoma (PTC).13 different oncogenic RET/PTC fusion proteins have been discovered [1]. Among them, RET/PTC1 accounts for about 60% of RET-related PTC, RET/PTC3 accounts for about 30%, and RET/PTC2 accounts for about 10%. The remaining RET/PTC family members are extremely rare. RET FUSION AND TREATMENT OF THYROID CARCINOMA The incidence of RET/PTC fusion in sporadic PTC is 15%-20%, and the malignant diagnosis rate for Bethesda III nodules is 60%. There is no false positive, which indicates that RET/PTC fusion is a very specific marker of PTC diagnosis [2], that can assist in the diagnosis of benign and malignant thyroid FNA samples. RET fusion also has a suggestive effect on the efficacy of targeted therapy. In 2020, the FDA successively approved Selpercatinib and Pralsetinib for the systemic treatment of RET fusion-positive thyroid cancer patients, and approved RET fusion testing as a companion diagnosis. DETECTION SIGNIFICANCE 1. FNA samples of thyroid nodules, coarse needle puncture samples or surgical resection samples for RET gene fusion detection can help assist in the diagnosis of PTC.